Amai Proteins' sweelin® Approved for Sale in Israel, Opening the Market to a New Generation of Reduced-Sugar Food and Beverage Products
Third regulatory approval in less than six months enables food and beverage manufacturers to commercialize products sweetened with sweelin® in Israel. REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Amai Proteins announces that the Israeli Ministry...
sweelin® Clinical Trial Results Published in Leading Journal, Food Chemistry, Confirming Blood Glucose Safety
This world's first clinical study on sweet proteins, reflects the clinical relevance of Amai Protein's sweelin®. The double-blind, randomized, crossover clinical study confirmed that sweelin® does not affect blood glucose, insulin and GLP-1 levels...
sweelin® Approved in Singapore as a Food Additive expanding Amai Proteins' Regulatory Footprint into Asia
Amai Proteins has achieved a major regulatory milestone with the Singapore Food Agency (SFA) approval of sweelin®, its flagship sweet protein, for use as a sweetening agent in food and beverage products. sweelin® is a next-generation sweet protein...
sweelin® is now FDA GRAS Approved, Clearing the Path for Accelerated U.S. Commercialization
Amai Proteins announces a major milestone for sweelin® in the U.S. market. The U.S. FDA has completed its review of the GRAS (Generally Recognized as Safe) notice for sweelin® and confirmed it has no safety concerns regarding the use of sweelin® as...
Amai Proteins succesfully completed world's first human clinical trial on effects of sweet proteins, with sweelin®
REHOVOT, Israel, Dec. 17, 2024 /PRNewswire/ -- Amai Proteins, a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of their...